Literature DB >> 26116366

Cancer immunoediting: A process driven by metabolic competition as a predator-prey-shared resource type model.

Irina Kareva1, Faina Berezovskaya2.   

Abstract

It is a well-established fact that tumors up-regulate glucose consumption to meet increasing demands for rapidly available energy by upregulating a purely glycolytic mode of glucose metabolism. What is often neglected is that activated cytotoxic cells of the immune system, integral players in the carcinogenesis process, also come to rely on glycolysis as a primary mode of glucose metabolism. Moreover, while cancer cells can revert back to aerobic metabolism, rapidly proliferating cytotoxic lymphocytes are incapable of performing their function when adequate resources are lacking. Consequently, it is likely that in the tumor microenvironment there may exist competition for shared resources between cancer cells and the cells of the immune system, which may underlie much of tumor-immune dynamics. Proposed here is a model of tumor-immune-glucose interactions, formulated as a predator-prey-common resource type system. The outcome of these interactions ranges from tumor elimination, to tumor dormancy, to unrestrained tumor growth. It is also predicted that the process of tumor escape can be preceded by periods of oscillatory tumor growth. A detailed bifurcation analysis of three subsystems of the model suggest that oscillatory regimes are a result of competition for shared resource (glucose) between the predator (immune cells) and the prey (cancer cells). Existence of competition for nutrients between cancer and immune cells may provide additional mechanistic insight as to why the efficacy of many immunotherapies may be limited.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer ecology; Cancer metabolism; Immune suppression; Immunoediting; Mathematical model; Predator–prey; Warburg effect

Mesh:

Year:  2015        PMID: 26116366     DOI: 10.1016/j.jtbi.2015.06.007

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  10 in total

1.  Global Dynamics of a Breast Cancer Competition Model.

Authors:  Kristen Abernathy; Zachary Abernathy; Arden Baxter; Meghan Stevens
Journal:  Differ Equ Dyn Syst       Date:  2017-01-20

Review 2.  Tumour immunotherapy: lessons from predator-prey theory.

Authors:  Phineas T Hamilton; Bradley R Anholt; Brad H Nelson
Journal:  Nat Rev Immunol       Date:  2022-05-05       Impact factor: 53.106

3.  A PDE Model of Breast Tumor Progression in MMTV-PyMT Mice.

Authors:  Navid Mohammad Mirzaei; Zuzana Tatarova; Wenrui Hao; Navid Changizi; Alireza Asadpoure; Ioannis K Zervantonakis; Yu Hu; Young Hwan Chang; Leili Shahriyari
Journal:  J Pers Med       Date:  2022-05-17

4.  Natural Killer Cell Education Is Associated With a Distinct Glycolytic Profile.

Authors:  Caroline Pfeifer; Andrew J Highton; Sven Peine; Jürgen Sauter; Alexander H Schmidt; Madeleine J Bunders; Marcus Altfeld; Christian Körner
Journal:  Front Immunol       Date:  2018-12-19       Impact factor: 7.561

5.  Dynamics of Breast Cancer under Different Rates of Chemoradiotherapy.

Authors:  Sara B Mkango; Nyimvua Shaban; Eunice Mureithi; Twalib Ngoma
Journal:  Comput Math Methods Med       Date:  2019-09-11       Impact factor: 2.238

Review 6.  Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy.

Authors:  Evelien A J van Genugten; Jetty A M Weijers; Sandra Heskamp; Manfred Kneilling; Michel M van den Heuvel; Berber Piet; Johan Bussink; Lizza E L Hendriks; Erik H J G Aarntzen
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

7.  Primary and metastatic tumor dormancy as a result of population heterogeneity.

Authors:  Irina Kareva
Journal:  Biol Direct       Date:  2016-08-23       Impact factor: 4.540

8.  Mathematical Modeling of the Function of Warburg Effect in Tumor Microenvironment.

Authors:  Milad Shamsi; Mohsen Saghafian; Morteza Dejam; Amir Sanati-Nezhad
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

Review 9.  A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.

Authors:  Irina Kareva
Journal:  Int J Mol Sci       Date:  2017-10-13       Impact factor: 5.923

Review 10.  How Should Cancer Models Be Constructed?

Authors:  Robert A Beckman; Irina Kareva; Frederick R Adler
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.